Science Times Observer
SEE OTHER BRANDS

Your top news on science and technology

Science Times Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.

Press releases published on May 14, 2025

Apache Corporation Tree Grant Program Opens U.S. Applications for 2025-2026 Planting Season

Apache Corporation Tree Grant Program Opens U.S. Applications for 2025-2026 Planting Season

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Apache Corporation, a subsidiary of APA Corporation (Nasdaq: APA), today announced the opening of applications for the Apache Corporation Tree Grant Program’s 2025-2026 planting season. To receive tree grants, …

Jasper Therapeutics to Present at Upcoming Investor Conferences

Jasper Therapeutics to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using …

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean …

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using …

Battalion Oil Corporation Announces First Quarter 2025 Financial and Operating Results

Battalion Oil Corporation Announces First Quarter 2025 Financial and Operating Results

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the first quarter of 2025. Key Highlights Generated first quarter 2025 sales volumes …

Navitas Semiconductor Appoints Cristiano Amoruso to Board of Directors

Navitas Semiconductor Appoints Cristiano Amoruso to Board of Directors

TORRANCE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the only pure-play, next-generation power semiconductor company and industry leader in gallium nitride (GaN) power ICs and silicon carbide (SiC) technology, today …

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and …

Kronos Worldwide, Inc. Announces Quarterly Dividend and Results of Annual Stockholder Meeting

Kronos Worldwide, Inc. Announces Quarterly Dividend and Results of Annual Stockholder Meeting

Dallas, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE:  KRO) announced that its board of directors has declared a regular quarterly dividend of five cents ($0.05) per share on its common stock, payable on June 18, 2025 to …

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in …

HP Inc. Declares Dividend

HP Inc. Declares Dividend

PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) has declared a cash dividend of $0.2894 per share on the company’s common stock. The dividend, the third in HP’s fiscal year 2025, is payable on July 2, 2025, to stockholders of record …

Northrop Grumman to Host Virtual Annual Shareholders Meeting

Northrop Grumman to Host Virtual Annual Shareholders Meeting

FALLS CHURCH, Va., May 14, 2025 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) will conduct its annual shareholders meeting exclusively online on Wednesday, May 21 at 8 a.m. Eastern time. You may access the virtual meeting by following this …

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in …

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today …

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and  Provides Business Highlights

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN …

USA Rare Earth Reports its First Quarter 2025 Financial Results

USA Rare Earth Reports its First Quarter 2025 Financial Results

STILLWATER, Okla., May 14, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (“USAR” or the “Company”) today announced its financial results for the first quarter ended March 31, 2025.  First Quarter Highlights  Merged with Inflection Point and …

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study  for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity …

Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2025 Results

Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2025 Results

ROSEVILLE, Minn., May 14, 2025 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) today announced fourth quarter and full-year results for its fiscal year ended March 30, 2025. Fourth Quarter Fiscal Year 2025 Highlights: Record fourth quarter sales of $245.3 …

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

WILMINGTON, Del., May 14, 2025 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service